Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. The TIFDED Study Group.
A pilot study was performed to compare the thromboprophylactic effect of danaparoid, enoxaparin and dalteparin in patients with hip fracture. The study was a prospective, randomised assessor-blind, four-centre trial. Prophylaxis was given for 9-11 days, whereafter bilateral phlebography was performed. A total of 197 patients were randomised. There were no statistically significant differences in the frequency of deep vein thrombosis, in blood loss or bleeding complications between the three prophylaxis groups. In conclusion, this moderately sized study revealed no statistically significant difference in efficacy or safety between danaparoid, enoxaparin and dalteparin in patients undergoing hip fracture surgery.
D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D000990:Antithrombin III / Q000008:administration & dosage / Q000009:adverse effects; D016063:Blood Loss, Surgical; D002809:Chondroitin Sulfates / Q000008:administration & dosage / Q000009:adverse effects; D017985:Dalteparin / Q000008:administration & dosage / Q000009:adverse effects; D003871:Dermatan Sulfate / Q000008:administration & dosage / Q000009:adverse effects; D004338:Drug Combinations; D004341:Drug Evaluation; D017984:Enoxaparin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000139:chemically induced; D006497:Heparan Sulfate / Q000008:administration & dosage / Q000009:adverse effects; D006620:Hip Fractures / Q000150:complications / Q000601:surgery*; D006801:Humans; D015994:Incidence; D008297:Male; D010865:Pilot Projects; D011446:Prospective Studies; D015996:Survival Rate; D013923:Thromboembolism / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D020246:Venous Thrombosis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*
D000925:Anticoagulants; D000990:Antithrombin III; D002809:Chondroitin Sulfates; D017985:Dalteparin; D003871:Dermatan Sulfate; D004338:Drug Combinations; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006497:Heparan Sulfate; C035838:danaparoid